The genetic testing market size in Europe is expected to grow from USD 18.51 billion in 2023 to USD 29.18 billion by 2028, growing at a CAGR of 9.52% during the forecast period. The European genetic testing market is growing continuously due to chronic disorders, cancer disease, and advanced diagnosis technology in Europe.
The increasing prevalence of genetic diseases is bringing people awareness and propelling the growth of the genetic testing market. Genetic testing identifies the variation in genes, chromosomes, and proteins, determining the genetic condition or chance of developing a genetic disorder. The increasing technological advancements for the diagnosis and testing of genetic disorders are driving the growth of the value of the genetic testing market. A large number of tests are available for the screening of various genetic diseases. Carrier testing, newborn screening, predictive and pre-symptomatic testing, and other scenarios have gained traction recently. The European genetic testing market is growing due to early detection and prevention, increasing the adoption of genetic testing in oncology. In February 2022, the European Commission published four new European Union Cancer Plan Activities, which help the other states address inequalities, improve the screening and vaccination of Human Papillomavirus Infection, and support cancer survivors.
The increasing adoption of next-generation sequencing is a significant tool for precise insight into tumors and specific receptors. Next-generation sequencing is advantageous in providing accuracy, sensitivity, and rapid results compared to the traditional methods in oncology. These factors are accelerating the growth of genetic testing in Europe.
The increasing investments in the research and development activities by the market players and the European healthcare system are creating opportunities for the development of the genetic testing market in the forecast period. The product launches, collaborations, and acquisitions related to genetic testing are expected to boost the market share value over the forecast period.
Genetic testing is expensive and not covered in health insurance and reimbursement policies, hampering the European genetic testing market value. The cost of genetic testing depends on the targeted disease it is being tested based on its nature and complexity. The cost of neonatal screening depends upon the government of the region.
The major challenge for expanding the genetic testing market is the negative impact produced by the results. The results increase the stress and anxiety in the people and disrupt the personal family relationships.
COVID-19 Impact on the Europe Genetic Testing Market:
COVID-19 positively impacted genetic testing in the early stage of the Pandemic, where genetic testing helped identify the variations, which led to the discovery of new therapies to reduce the spread of the virus. For instance, Genomtec launched a genetic diagnostic kit for the identification of SARS-Cov-2 infection through the saliva of patients in the European Union. Thus, the Pandemic positively impacted the market growth by introducing various genetic testing kits.
The research report on the European genetic testing market has been segmented and sub-segmented into the following categories.
The cancer testing segment held the largest share of the European genetic testing market revenue and is expected to maintain its domination in the forecast period. Genetic testing highly benefits the oncology department compared to other departments. The early detection and prevention of increasing demand for personalized medicines is driving genetic testing in cancer testing. Next-generation sequencing (NGS), a type of genetic testing, is viral in oncology to identify individual tumors and specific receptors.
Prenatal testing has been gaining traction in recent years. According to a study published in Prenatal Diagnosis in March 2021, the Pandemic had influenced many pregnant women on prenatal genetic testing. These developments and new launches are accelerating the growth of market size.
The diagnostic testing segment dominated the market in 2022 by holding a significant share of the European genetic testing market. The increasing prevalence of chronic diseases drives market growth as early diagnosis helps reduce complications. According to the European Cancer Information System, the new cancer cases in Europe are estimated to reach 3.13 million by 2035. The increasing number of cases of cancer is raising the demand for diagnostic testing for cancers in Europe. The increasing number of innovative product launches in diagnostic testing is boosting the market growth. For instance, In February 2021, the launch of the COVID-19 blood test assisted the hospitals in identifying the patients with higher risks in Europe.
The UK dominated the European genetic testing market due to increasing emphasis on early detection and prevention of diseases. The growing adoption of genetic testing in oncology is driving the market growth. The increasing benefits of genetic testing in identifying rare diseases are raising the adoption of genetic testing in the region. In March 2022, the first UK pilot study of newborn screening for spinal muscular atrophy was launched in Oxford. Germany held the second position in the European market due to its developed healthcare infrastructure. The introduction of technological advancements in diagnostic testing and treatment is propelling the German genetic testing market.
France and Spain are projected to have significant growth rates over the forecast period due to increasing developments in research activities, enhancing the adoption of genetic testing. In April 2022, Illumina Inc., a DNA sequencing company and array-based technologies, acquired an agreement with Germany Hannover Medical School to implement whole-genome sequencing in critical cases of genetic disease in children. Italy and Russia, developed countries, are expected to have decent growth in the forecast period due to increasing chronic disease conditions and the influence of the Pandemic on prenatal genetic testing procedures.
KEY MARKET PLAYERS:
A few of the noteworthy companies operating in the European genetic testing market profiled in this report are Abbott Laboratories, Roche Molecular Diagnostics Inc., Abbott Molecular Inc., AutoGenomics Inc., Celera Group, ELITech Group, BioRad Laboratories, PerkinElmer Inc., Roche Diagnostics Corp., Quest Diagnostics Inc., Transgenomic Inc., and Applied Biosystems Inc.
Due to the factors such as advancements in technology, increasing public awareness, and the growing emphasis on personalized medicine, the demand for genetic testing in Europe has grown significantly.
Factors such as limited access to testing in some areas, high costs, and limited reimbursement for testing are some of the major challenges to the European genetic testing market.
The growing demand for non-invasive prenatal testing, the increasing use of genetic testing in personalized medicine, and the growing interest in pharmacogenetic testing are some of the current trends in the European genetic testing market.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: [email protected]